Crossmark Global Holdings Inc. Sells 6,353 Shares of Amgen, Inc. (NASDAQ:AMGN)

Crossmark Global Holdings Inc. trimmed its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 10.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,324 shares of the medical research company’s stock after selling 6,353 shares during the period. Crossmark Global Holdings Inc.’s holdings in Amgen were worth $10,706,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in AMGN. Advisors Preferred LLC purchased a new stake in Amgen in the 2nd quarter worth about $30,000. Arbor Wealth Management LLC grew its holdings in Amgen by 154.5% during the 2nd quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock valued at $31,000 after buying an additional 102 shares in the last quarter. Ashburton Jersey Ltd purchased a new position in Amgen during the 2nd quarter valued at about $42,000. Sound Income Strategies LLC grew its holdings in Amgen by 402.1% during the 2nd quarter. Sound Income Strategies LLC now owns 236 shares of the medical research company’s stock valued at $43,000 after buying an additional 189 shares in the last quarter. Finally, Next Capital Management LLC grew its holdings in Amgen by 42.5% during the 2nd quarter. Next Capital Management LLC now owns 238 shares of the medical research company’s stock valued at $44,000 after buying an additional 71 shares in the last quarter. Institutional investors own 76.24% of the company’s stock.

A number of research analysts have weighed in on the company. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a report on Tuesday. Cantor Fitzgerald set a $230.00 target price on Amgen and gave the company a “hold” rating in a report on Monday, September 30th. Citigroup reaffirmed a “buy” rating on shares of Amgen in a report on Monday, August 12th. Goldman Sachs Group set a $243.00 target price on Amgen and gave the company a “buy” rating in a report on Monday, September 30th. Finally, Morgan Stanley reduced their target price on Amgen from $211.00 to $207.00 and set an “overweight” rating for the company in a report on Monday, July 15th. Eleven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Amgen has an average rating of “Hold” and a consensus target price of $217.41.



In related news, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total value of $77,792.00. Following the completion of the sale, the director now owns 16,336 shares in the company, valued at approximately $2,990,141.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $206.70, for a total value of $413,400.00. Following the completion of the sale, the director now owns 16,336 shares of the company’s stock, valued at approximately $3,376,651.20. The disclosure for this sale can be found here. Insiders have sold 17,851 shares of company stock valued at $3,671,900 in the last three months. 0.25% of the stock is owned by insiders.

Shares of NASDAQ AMGN traded up $0.61 during midday trading on Wednesday, hitting $196.69. 936,351 shares of the company’s stock were exchanged, compared to its average volume of 2,991,597. Amgen, Inc. has a 12-month low of $166.30 and a 12-month high of $211.90. The company has a current ratio of 2.89, a quick ratio of 2.60 and a debt-to-equity ratio of 2.58. The company has a market cap of $117.30 billion, a price-to-earnings ratio of 13.66, a PEG ratio of 2.54 and a beta of 1.11. The business’s fifty day moving average price is $199.86 and its two-hundred day moving average price is $186.12.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The company had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the previous year, the firm earned $3.83 earnings per share. Amgen’s revenue was down 3.1% on a year-over-year basis. Equities analysts expect that Amgen, Inc. will post 14.31 earnings per share for the current fiscal year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: Risk Tolerance and Your Investment Decisions

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.